Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Greg Pyszczymuka is Chief Commercial Officer at Aytu Biopharma. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jul 30, 2026, each linked to the official Form 4.
Chief Commercial Officer
Disclosures on record
1
Companies involved
1
Aytu BiopharmaAYTU
Jul 28, 202620Kdisclosed Jul 30
DetailsOfficial recordAs of the latest filing on , Greg Pyszczymuka reported holding 56,102 shares of Aytu Biopharma (AYTU), worth about $149K at the last close of $3 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Aytu Biopharma AYTU | 56,102 | 56K direct | $3 | $149K | Jul 28, 2026 |
Is this Greg Pyszczymuka’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Greg Pyszczymuka bought shares on the open market in 2022 and 2023, and has not bought since 2023.
Greg Pyszczymuka reported 2 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $22K1×1 trade | — |
| 2022 | $24K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jul 28, 2026, Greg Pyszczymuka reported holding 56,102 shares of Aytu Biopharma (AYTU). At the last close of $3 on Nov 17, 2026, that is about $149K. This is the stake disclosed in filings, not a net worth.
Greg Pyszczymuka bought shares on the open market in 2022 and 2023, and has not bought since 2023.
In SEC filings since 2022: the latest open-market purchase is from 2023; no open-market sale is on record.
Aytu Biopharma (AYTU), from 2022 to 2023: 2 purchases and 0 sales.
Greg Pyszczymuka reported 2 open-market purchases and 0 sales here, 2022 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.